Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:22341446  

Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.

Baochun Zhang | Sven Kracker | Tomoharu Yasuda | Stefano Casola | Matthew Vanneman | Cornelia Hömig-Hölzel | Zhe Wang | Emmanuel Derudder | Shuang Li | Tirtha Chakraborty | Shane E Cotter | Shohei Koyama | Treeve Currie | Gordon J Freeman | Jeffery L Kutok | Scott J Rodig | Glenn Dranoff | Klaus Rajewsky
Cell | 2012

B cells infected by Epstein-Barr virus (EBV), a transforming virus endemic in humans, are rapidly cleared by the immune system, but some cells harboring the virus persist for life. Under conditions of immunosuppression, EBV can spread from these cells and cause life-threatening pathologies. We have generated mice expressing the transforming EBV latent membrane protein 1 (LMP1), mimicking a constitutively active CD40 coreceptor, specifically in B cells. Like human EBV-infected cells, LMP1+ B cells were efficiently eliminated by T cells, and breaking immune surveillance resulted in rapid, fatal lymphoproliferation and lymphomagenesis. The lymphoma cells expressed ligands for a natural killer (NK) cell receptor, NKG2D, and could be targeted by an NKG2D-Fc fusion protein. These experiments indicate a central role for LMP1 in the surveillance and transformation of EBV-infected B cells in vivo, establish a preclinical model for B cell lymphomagenesis in immunosuppressed patients, and validate a new therapeutic approach.

Pubmed ID: 22341446

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: CA078378
  • Agency: NCI NIH HHS, United States
    Id: CA098285
  • Agency: NCI NIH HHS, United States
    Id: P01 CA078378
  • Agency: NCI NIH HHS, United States
    Id: P01 CA155258
  • Agency: NCI NIH HHS, United States
    Id: R01 CA143083
  • Agency: NCI NIH HHS, United States
    Id: P50 CA100707
  • Agency: NIAID NIH HHS, United States
    Id: AI56299
  • Agency: NCI NIH HHS, United States
    Id: R01 CA098285
  • Agency: NCI NIH HHS, United States
    Id: P01 CA078378-02
  • Agency: NIAID NIH HHS, United States
    Id: P01 AI056299
  • Agency: NCI NIH HHS, United States
    Id: R01 CA098285-01A1
  • Agency: NIAID NIH HHS, United States
    Id: P01 AI056299-06A1
  • Agency: NCI NIH HHS, United States
    Id: R01 CA050947

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Miltenyi Biotec (tool)

RRID:SCR_008984

An Organization portal, Antibody supplier, Service resource,

View all literature mentions